(CIDRAP News) Half-dose influenza shots generate nearly as strong an immune response in young adults as full-dose shots do, suggesting that cutting the dose in half may be a good way to cope with vaccine shortages, according to a study published this week.
(CIDRAP News) In the influenza pandemic of 1918, those who got sick in the first wave of illness were up to 94% less likely to fall ill when the second and much more severe wave struck, according to a new analysis of historical data.
(CIDRAP News) – Emergent BioSolutions announced today that it has received a $29.7 million contract from the federal government to continue work on another of its next-generation anthrax vaccine candidates.
(CIDRAP News) – Xoma Ltd., a Berkeley, Calif., pharmaceutical company, recently announced that it received a $65 million multiyear federal contract to fund work on botulinum antitoxins, one of which it hopes to put through safety and efficacy tests starting in 2009.
(CIDRAP News) SIGA Technologies Inc. announced this week that it has been awarded a $55 million federal contract to develop a new formulation of its experimental smallpox drug, called ST-246, and carry out related efforts.
The company, based in New York City, said it had previously received a $16.5 million contract to develop the drug, described as "a potent, non-toxic inhibitor of orthopoxviruses."
(CIDRAP News) US Navy and Air Force officials recently reported a suspension of work in their biodefense laboratories to allow a thorough review of safety procedures, following the Army's announcement in early August that it would review security measures at the lab that housed the work of the late Bruce E. Ivins, whom federal officials believe played a role in the 2001 anthrax attacks.
(CIDRAP News) It was secondary bacterial pneumonianot the influenza virus by itselfthat killed most of the millions who perished in the 1918 flu pandemic, which suggests that current pandemic preparations should include stockpiling of antibiotics and bacterial vaccines, influenza researchers reported this week.
(CIDRAP News) A study of the blood of older people who survived the 1918 influenza pandemic reveals that antibodies to the strain have lasted a lifetime and can perhaps be engineered to protect future generations against similar strains.
(CIDRAP News) Scientists have warned it's impossible to predict which avian influenza virus will spark the next pandemic, and while most of the attention has been on highly pathogenic H5N1, one research group is reporting new findings that raise concerns about the threat from the low-pathogenic H9N2 virus.